Respiratory Medicine Case Reports
Tezepelumab in severe asthma with pulmonary mucus plugs and eosinophilic chronic rhinosinusitis after dupilumab intolerance and suboptimal mepolizumab response: A case report
By Satoru Senoo, Kei Fukushima, Kohei Takata and 7 others.
Abstract
Background
Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has demonstrated efficacy in the treatment of severe asthma and chronic rhinosinusitis with nasal polyps. However, real-world evidence remains limited, particularly for patients with eosinophilic chronic rhinosinusitis (ECRS) who exhibit inadequate or unfavorable responses to other biologics.
